Ho Yeong Lim
林昊荣
MD, PhD
Professor of Hematology-Oncology血液肿瘤科教授
👥Biography 个人简介
Ho Yeong Lim is a leading Korean HCC oncologist renowned for his work on targeted therapies and outcomes in Asian HCC patients. He has led pivotal trials for brivanib and other novel agents and contributed extensively to HCC treatment guidelines in Korea and Asia.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Targeted Therapy Trials in HCC
Led Korean and Asia-Pacific trials of brivanib and other VEGFR/FGFR inhibitors, generating key data on efficacy in HBV-related HCC.
Asian HCC Patient Outcomes
Conducted landmark studies characterizing HCC prognosis and treatment response differences between Asian and Western patient populations.
HCC Korean Guidelines
Served on the Korean Liver Cancer Association guideline committee, shaping national standards for HCC diagnosis, staging, and systemic treatment.
Representative Works 代表性著作
Brivanib in patients with advanced HCC who were resistant to sorafenib
Journal of Clinical Oncology (2012)
Established proof of concept for second-line VEGFR/FGFR inhibition and informed subsequent second-line HCC trial designs.
Efficacy and safety of regorafenib in Korean HCC patients after sorafenib failure
Liver Cancer (2018)
Confirmed regorafenib benefit in Asian HCC patients, supporting its adoption in Korean and regional treatment guidelines.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 林昊荣 的研究动态
Follow Ho Yeong Lim's research updates
留下邮箱，当我们发布与 Ho Yeong Lim（Samsung Medical Center, Sungkyunkwan University School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment